含雷贝拉唑与枸橼酸铋雷尼替丁的两种三联疗法治疗消化性溃疡的疗效比较

目的:比较含雷贝拉唑(RAZ)与枸橼酸铋雷尼替丁(RBC)的两种三联疗法治疗消化性溃疡的临床疗效。方法:将确诊为消化性溃疡的患者148例按随机数字表法均分为RAZ组和RBC组,分别给予RAZ/RBC+克拉霉素+甲硝唑的三联疗法治疗1周,之后两组患者均单服RAZ或RBC治疗3周,疗程共4周。治疗结束后比较两组患者的疗效、溃疡愈合率和幽门螺杆菌(Hp)根除情况,并观察治疗中的不良反应。结果:治疗结束后,RAZ组与RBC组患者的临床总有效率分别为88.7%、83.3%,Hp根除率分别为87.3%、93.1%,溃疡愈合率分别为85.9%、87.5%,两组比较差异均无统计学意义(P>0.05)。两组患者的不良反应均较轻,不影响治疗,可自行好转。结论:含RAZ与RBC的两种三联疗法治疗消化性溃疡的疗效相当,且安全性均较好。

Comparison of Clinical Efficacy of Rabeprazole vs. Ranitidine Bismuth Citrate in the Treatment of Peptic Ulcer

OBJECTIVE： To compare the clinical efficacy of triple therapy of rabeprazole （RAZ） and ranitidine bismuth citrate （RBC） for peptic ulcer. METHODS： 148 patients diagnosed as peptic ulcer in gastroenterology department of our hospital were admitted into RAZ group and RBC group with 74 cases in each group. They were given triple therapy of RAZ or RBC＋clarithromycin＋metronidazole for a week, and then received RAZ or RBZ alone for 3 weeks. Treatment course of 2 groups lasted for 4 weeks. After treatment, therapeutic efficacy, ulcer healing and Hp eradication were compared between 2 groups. ADR of them was observed during treatment. RESULTS： After treatment, total effective rates of RAZ group and RBC group were 88.7% and 83.3%; Hp eradication rates were 87.3 % and 93.1%; ulcer healing rates were 85.9% and 87.5%, respectively; there was no statistical significance （P〉0.05）. ADR of 2 groups was mild and can be recovered automatically, and treatment was not influenced. CONCLUSIONS ： Triple therapy of both RZA and RBC are effective and safe for peptic ulcer.